Active Recombinant Human TNFSF14 protein, hFc-Myc-tagged

Cat.No. : TNFSF14-4603H
Product Overview : Recombinant Human TNFSF14 protein(O43557)(74-240aa), fused to N-terminal hFc tag and Myc tag, was expressed in Mammalian cell.
  • Specification
  • Gene Information
  • Related Products
  • Download
Source : Mammalian cell
Species : Human
Tag : Fc&Myc
Form : If the delivery form is liquid, the default storage buffer is Tris/PBS-based buffer, 5%-50% glycerol. If the delivery form is lyophilized powder, the buffer before lyophilization is Tris/PBS-based buffer, 6% Trehalose, pH 8.0.
Bio-activity : Measured by its binding ability in a functional ELISA. Immobilized TNFRSF14 at 5 μg/ml can bind TNFSF14, the EC50 is 45.44-53.29 ng/ml.
Molecular Mass : 46.7 kDa
Protein length : 74-240aa
AA Sequence : DGPAGSWEQLIQERRSHEVNPAAHL TGANSSLTGSGGPLLWETQLGLAFL RGLSYHDGALVVTKAGYYYIYSKVQ LGGVGCPLGLASTITHGLYKRTPRY PEELELLVSQQSPCGRATSSSRVWW DSSFLGGVVHLEAGEKVVVRVLDER LVRLRDGTRSYFGAFMV
Endotoxin : Less than 1.0 EU/ug as determined by LAL method.
Purity : Greater than 88% as determined by SDS-PAGE.
Storage : Store at -20°C upon receipt, aliquoting is necessary for mutiple use. Avoid repeated freeze-thaw cycles.
Reconstitution : Reconstitute protein in deionized sterile water to a concentration of 0.1-1.0 mg/mL.We recommend to add 5-50% of glycerol (final concentration) and aliquot for long-term storage at -20°C/-80°C.
Gene Name : TNFSF14 tumor necrosis factor (ligand) superfamily, member 14 [ Homo sapiens ]
Official Symbol : TNFSF14
Synonyms : TNFSF14; tumor necrosis factor (ligand) superfamily, member 14; tumor necrosis factor ligand superfamily member 14; CD258; HVEM L; LIGHT; LTg; delta transmembrane LIGHT; herpesvirus entry mediator A; herpesvirus entry mediator ligand; herpesvirus entry mediator-ligand; herpes virus entry mediator ligand; ligand for herpesvirus entry mediator; tumor necrosis factor receptor-like 2; tumor necrosis factor superfamily member LIGHT; TR2; HVEML;
Gene ID : 8740
mRNA Refseq : NM_003807
Protein Refseq : NP_003798
MIM : 604520
UniProt ID : O43557

For Research Use Only. Not intended for any clinical use. No products from Creative BioMart may be resold, modified for resale or used to manufacture commercial products without prior written approval from Creative BioMart.

Inquiry

  • Reviews
  • Q&As

Customer Reviews (3)

Write a review
Reviews
07/28/2020

    The extended longevity of results gave us the confidence to delve deeper into complex biological processes.

    08/01/2018

      It was reassuring to know that the product's effects persisted, allowing for thorough and comprehensive research.

      06/19/2016

        The ability to obtain enduring results positively influenced the depth of our investigations.

        Q&As (7)

        Ask a question
        What are the primary changes induced by TNFSF14 in the tumor microenvironment? 05/19/2022

        TNFSF14, when delivered to or expressed within tumors, causes significant changes primarily through vascular normalization and generation of tertiary lymphoid structures.

        What challenges remain in utilizing TNFSF14 for cancer immunotherapy? 07/02/2021

        While investigators have used multiple vectors to deliver TNFSF14 to tumor tissues, there are still improvements needed, and components within the human tumor microenvironment may impede translational efforts.

        What does TNFSF14 stand for? 02/05/2021

        TNFSF14 stands for Tumor Necrosis Factor Superfamily Member 14.

        How can TNFSF14 synergize with other immunotherapy modalities? 02/22/2020

        TNFSF14's changes in the tumor microenvironment can synergize with methods inducing anti-tumor immune responses, such as checkpoint inhibitors and tumor vaccines, improving immunotherapeutic strategies against cancer.

        In what context has TNFSF14 been utilized to combat cancer? 02/06/2018

        TNFSF14 has been used in multiple tumor models, where it can be combined with other immunotherapy modalities to clear established solid tumors and treat metastatic events.

        How long has TNFSF14 been in pre-clinical development? 06/11/2017

        TNFSF14 has been in pre-clinical development for over a decade.

        What is the primary promise of TNFSF14 in the field of cancer immunotherapy? 08/15/2016

        TNFSF14 shows promise in enhancing treatment approaches in cancer immunotherapy.

        Ask a Question for All TNFSF14 Products

        Required fields are marked with *

        My Review for All TNFSF14 Products

        Required fields are marked with *

        0

        Inquiry Basket

        cartIcon
        logo

        FOLLOW US

        Terms and Conditions        Privacy Policy

        Copyright © 2024 Creative BioMart. All Rights Reserved.

        Contact Us

        • /
        • Service lnquiry:

        Stay Updated on the Latest Bioscience Trends